Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

By Vaishampayan Ulka   Heilbrun Lance   Shields Anthony   Lawhorn-Crews Jawana   Baranowski Karen   Smith Daryn   Flaherty Lawrence  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 69-75

Springer Publishing Company

Access to resources Recommend Favorite

Thalidomide in multiple myeloma

By García-Sanz Ramón  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 195-213

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in Multiple Myeloma

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 431-440

Bentham Science Publishers

Access to resources Recommend Favorite

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response

By Rifkin Robert  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 714-722

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma

By Olencki Thomas   Malhi Sareena   Mekhail Tarek   Dreicer Robert   Elson Paul   Wood Laura   Bukowski Ronald  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 321-326

Springer Publishing Company

Access to resources Recommend Favorite